Antitumor anthraquinone analogues for multidrug resistant tumor cells

Journal of Medical Sciences

Volumn 26, Issue 1, 2006, Pages 1-4

  Preobrazhenskaya, Maria N ^a   Shchekotikhin, Andrey E ^a   Shtil, Alexander A ^b   Huang, Hsu Shan ^c  

^a GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^b N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Anthraquinone; Antibiotics; Cancer; Chemotherapy; Multidrug resistance

Indexed keywords

AMETANTRONE; ANTHRAQUINONE; DOXORUBICIN; MITOXANTRONE;

CHEMOTHERAPY; DRUG RESISTANCE; HUMAN; LEUKEMIA CELL LINE; MULTIDRUG RESISTANCE; REVIEW; TUMOR CELL;

EID: 33644893614     PISSN: 10114564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Li GW, Zhao ZY, Xu RS, Ying BP, Pan QC. [Studies on the chemical constituents of the root of Damnacanthus subspinosus Hand-Mazz. I. The isolation and structural determination of the subspinosin and 8-hydroxysubspinosin (author's transl)]. Yao Xue Xue Bao 1981;16:576-581.
2. Chang P, Lee KH, Shingu T, Hirayama T, Hall IH, Huang HC. Antitumor agents 50. 1 Morindaparvin-A, a new antileukemic anthraquinone, and alizarin-1-methyl ether from Morinda parvifolia, and the antileukemic activity of the related derivatives. J Nat Prod 1982;45:206-210.
3. Monneret C. Recent developments in the field of anti-tumour anthracyclines. Eur J Med Chem 2001;36:483-493.
4. Baguley BC. DNA intercalating anti-tumour agents. Anticancer Drug Des 1991;6:1-35.
5. Levine M, Eisen A. Anthracycline adjuvant chemotherapy: how much is enough? J Clin Oncol 2001;19:599-601.
6. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-741.
7. Gate L, Couvreur P, Nguyen-Ba G, Tapiero H. N-methylation of anthracyclines modulates their cytotoxicity and pharmacokinetic in wild type and multidrug resistant cells. Biomed Pharmacother 2003;57:301-308.
8. Zee-Cheng RK, Cheng CC. Structure-activity relationship study of anthraquinones: 1,4-dihydroxy-5,8-bis[[2-(2-hydroxyethoxy)ethyl]amino]-9,10- anthracenedione, an analog of an established antineoplastic agent. J Pharm Sci 1982;71:708-709.
9. Denny WA. Emerging DNA topisomerase inhibitors as anticancer drugs. Expert Opin Emerg Drugs 2004;9:105-133.
10. Gogas H, Mansi JL. New drugs. The anthrapyrazoles. Cancer Treat Rev 1996;21:541-552.
11. Hill BT, Hosking LK, Shellard SA, Whelan RD. Comparative effectiveness of mitoxantrone and doxorubicin in overcoming experimentally induced drug resistance in murine and human tumour cell lines in vitro. Cancer Chemother Pharmacol 1989;23:140-144.
12. Shchekotikhin AE, Buyanov VN, Preobrazhenskaya MN. Synthesis of 1-(omega-aminoalkyl)naphthoindolediones with antiproliferative properties. Bioorg Med Chem 2004;12:3923-3930.
13. Shchekotikhin AE, Shtil AA, Luzikov YN, Bobrysheva TV, Buyanov VN, Preobrazhenskaya MN. 3-Amino-methyl derivatives of 4,11-dihydroxynaphtho[2,3-f] indole-5,10-dione for circumvention of anticancer drug resistance. Bioorg Med Chem 2005;13:2285-2291.
14. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-967.